Galanin (1-13)-Spantide I CAS NO.143868-20-6
Galanin (1-13)-Spantide I CAS NO.143868-20-6
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Galanin (1-13)-Spantide I |
| CAS NO. | 143868-20-6 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C138H199N35O30 |
| Molecular Weight | 2828.34 g/mol |
| Purity (RP-HPLC) | ≥ 95.0% |
| Solubility | Soluble in water (≥5 mg/mL), dilute acetic acid, and DMSO |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Potent galanin receptor antagonist; blocks galanin-mediated signaling at GALR1, GALR2, and GALR3 receptors. |
| Storage Conditions | Store at -20°C to -80°C; avoid repeated freeze-thaw cycles. Reconstituted solution can be stored at 4°C for up to 1 week or at -20°C for up to 3 months. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Galanin (1-13) Fragment: Competitively binds to galanin receptors (GalR1, GalR2, GalR3), particularly at the N-terminal recognition site, blocking endogenous galanin from activating G protein-coupled signaling pathways (Gi/o-mediated cAMP inhibition and Gq-mediated calcium mobilization).
Spantide I Component: Acts as a competitive antagonist at neurokinin-1 (NK1) receptors, preventing substance P binding and subsequent activation of phospholipase C, protein kinase C, and inflammatory/neuroexcitatory pathways.
2.PRODUCT INDICATIONS
Pain Pathway Studies: Investigating synergistic/opposing roles of galanin and substance P in nociceptive transmission in acute, inflammatory, and neuropathic pain models.
Neurogenic Inflammation Research: Studying peptide-mediated inflammation where galanin and substance P co-modulate vascular permeability and immune cell activation.
Co-transmission Analysis: Examining functional interactions between galaninergic and tachykininergic systems in central and peripheral neurons.
Spinal Cord & DRG Research: Mapping and modulating peptide interactions in spinal nociceptive processing and sensory ganglia.
Receptor Cross-talk Studies: Investigating signaling interactions between GalR and NK1 receptor systems in neural circuits.
Prototype Therapeutic Screening: Evaluating dual antagonism as a potential strategy for chronic pain or neuroinflammatory conditions.
3.CLINICAL EFFICACY OF PRODUCT
Preclinical studies in rodent models demonstrate that this chimera produces more potent antinociceptive effects in inflammatory and neuropathic pain tests compared to individual galanin or NK1 antagonists alone, suggesting synergistic benefits of dual receptor blockade.
No human trials have been conducted with Galanin (1-13)-Spantide I. Its clinical efficacy is unknown, and its pharmacokinetic profile (including stability, blood-brain barrier penetration, and potential side effects) has not been characterized in humans.
Indirect therapeutic relevance lies in validating the dual receptor blockade concept for conditions like chronic pain, migraine, or neuroinflammatory disorders. However, any future drug development would require optimization of selectivity, pharmacokinetics, and safety profile, which this unmodified chimera lacks.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
May 25, 26
Premium API Oxandrolone Ucinky Manufacturing
Premium API Oxandrolone Ucinky Manufacturing Leading global supplier of high-purity chemical raw materials for pharmaceutical grade Oxandrolone Ucinky, combining precision engineering with industrial scale. 5000 kg Annual Output 120 Countries Served 5 Days Sample Lead Time 99.7 On-Time Delivery Industrial Precision Pure Chemical Synthesis Engineering the future of pharmaceutical intermediates with unmatched stability. Our facility stands as a global leader in the oxandrolone ucinky sector, utilizing CRYOGENIC CRYSTALLIZATION and advanced chromatography to ensure an assay purity exceeding 99.8. We integrate a fully automated closed-loop system that eliminates human error and contamination.
May 22, 26
Clinical Benefits and Applications of Oxandrolone Therapy
Oxandrolone therapy represents a sophisticated intersection of endocrine science and regenerative medicine, primarily utilized to address muscle wasting and metabolic dysfunction. In the global pharmaceutical landscape, this specific approach to androgen therapy is valued for its unique ability to promote protein synthesis while exhibiting a lower androgenic profile compared to traditional steroids, making it a critical tool for patients recovering from severe trauma or chronic illness. From a clinical perspective, understanding the nuances of oxandrolone therapy is essential for optimizing patient outcomes in weight gain and tissue repair.
May 20, 26
Clinical Benefits and Production of Oxandrolone Steroid
The global pharmaceutical landscape has seen a significant rise in the demand for highly specialized anabolic agents, among which the oxandrolone steroid stands out due to its unique chemical profile and therapeutic versatility. As a modified version of dihydrotestosterone, this compound provides a potent means of addressing muscle wasting and metabolic deficits, making it a critical asset in both clinical rehabilitation and advanced physiological research. Understanding the nuances of this synthetic compound is essential for healthcare providers and researchers alike, as it balances efficacy with a relatively lower androgenic profile compared to other steroids.
